title: Beta-adrenoceptor subtypes mediating the metabolic effects of BRL 35135 in man.
abstract: 1. The aim of the present study was to evaluate the metabolic responses produced in man by the beta 3-adrenoceptor agonist BRL 35135, and to determine which of these responses are beta 3-, rather than beta 1- or beta 2-, mediated. 2. Eight normal male subjects received single oral doses of BRL 35135 (8 mg) or the selective beta 2-adrenoceptor agonist salbutamol (8 mg) after pretreatment with placebo, bisoprolol (5 mg) as a selective beta 1-antagonist or nadolol (20 mg) to block beta 1- and beta 2-, but not beta 3-adrenoceptors. 3. BRL 35135 and salbutamol produced a significant fall in serum potassium concentration compared with placebo, in keeping with beta 2-adrenoceptor stimulation. Both drugs also produced a significant increase in serum glucose, insulin and lactate concentrations, which mirrored the hypokalaemic response, being unaffected by selective beta 1-blockade (bisoprolol), but completely blocked by nadolol. BRL 35135 (but not salbutamol) also produced a significant rise in serum free fatty acid and glycerol concentrations, which appeared to be beta 2-mediated. 4. A significant increase in basal metabolic rate occurred with both BRL 35135 and salbutamol. In the case of salbutamol, this effect appeared to be mediated solely by beta 2-adrenoceptors, whereas BRL 35135 produced a thermogenic response which could only be partially accounted for by a combination of beta 1- and beta 2-adrenoceptor stimulation. 5. These results infer the possibility of thermogenic beta 3-adrenoceptors in man, although these do not appear to be involved in the control of carbohydrate or fat metabolism.
authors.affiliation: Department of Clinical Pharmacology, Ninewells Hospital and Medical School, Dundee, Scotland, U.K.
authors.forename: N M
authors.initials: NM
authors.lastname: Wheeldon
authors.forename: D G
authors.initials: DG
authors.lastname: McDevitt
authors.forename: L C
authors.initials: LC
authors.lastname: McFarlane
authors.forename: B J
authors.initials: BJ
authors.lastname: Lipworth
mesh_terms: D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000328:Adult; D000420:Albuterol / Q000494:pharmacology; D001481:Basal Metabolism / Q000187:drug effects*; D017298:Bisoprolol / Q000494:pharmacology; D001786:Blood Glucose / Q000378:metabolism; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005990:Glycerol / Q000097:blood; D006801:Humans; D007328:Insulin / Q000097:blood; D007773:Lactates / Q000097:blood; D019344:Lactic Acid; D008297:Male; D009248:Nadolol / Q000494:pharmacology; D010627:Phenethylamines / Q000494:pharmacology*; D011188:Potassium / Q000097:blood; D016037:Single-Blind Method
chemical_list: D000318:Adrenergic beta-Agonists; D001786:Blood Glucose; D005230:Fatty Acids, Nonesterified; D007328:Insulin; D007773:Lactates; D010627:Phenethylamines; D019344:Lactic Acid; D009248:Nadolol; C063157:BRL 35135; D005990:Glycerol; D000420:Albuterol; D011188:Potassium; D017298:Bisoprolol